Nestle is launching protein shots in the United States which it says help suppress appetite for people looking to shed pounds ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 488.46% and ...

News of Merck’s licensing of Hansoh’s preclinical medicine pressured shares in Viking and other obesity drug developers seen ...

Merck & Co. has secured a licensing agreement with Chinese drugmaker Hansoh Pharma for an experimental oral weight-loss drug, ...

China’s Gan & Lee Pharmaceuticals has received FDA clearance to run a head-to-head Phase 2 study of its drug candidate GZR18 ...

A new class of weight loss drugs developed by Novo Nordisk and Eli Lilly “opens the possibility of an end to the obesity ...

Merck signed a deal worth up to $2 billion with Hansoh Pharma to develop and sell the Chinese biotech's oral obesity drug ...

Merck will pay Hansoh $112 million upfront for rights to the drug, with the potential for an additional $1.9 billion in ...

The company behind KitKat has launched a protein drink that it claims suppresses appetite in the same way as popular ...

Merck & Co. is licensing a potential oral obesity drug from Hansoh Pharma in a deal potentially worth more than $2 billion to the Chinese biopharmaceutical company.

With Novo Nordisk’s name already synonymous with treatments for diabetes and obesity, the Danish drugmaker has been making a ...